A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and ...
Prothena's fair value estimate has recently risen from $13 to $16.50, signaling renewed confidence in the company's prospects. This revised price target reflects analyst optimism about the near-term ...
Using the 2 Stage Free Cash Flow to Equity, Apyx Medical fair value estimate is US$5.54. Current share price of US$3.35 suggests Apyx Medical is potentially 40% unde ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback